A Double-blind, Randomized, Placebo-Controlled Phase 2a Trial of GRI-0621 in Patients With Chronic Liver Disease

Trial Profile

A Double-blind, Randomized, Placebo-Controlled Phase 2a Trial of GRI-0621 in Patients With Chronic Liver Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs GRI 0621 (Primary)
  • Indications Hepatitis B; Hepatitis C; Liver disorders; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms GRI-201
  • Sponsors GRI Bio
  • Most Recent Events

    • 16 Feb 2018 Last checked against ClinicalTrials.gov record.
    • 13 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 13 Feb 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top